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The genetic control of skeletal muscle differentiation at the onset of myogenesis in the embryo is relatively well understood compared to the
formation of muscle during the fetal period giving rise to the bulk of skeletal muscle fibers at birth. The Mlc1f/3f (Myl1) locus encodes two alkali
myosin light chains, Mlc1f and Mlc3f, from two promoters that are differentially regulated during development. The Mlc1f promoter is active in
embryonic, fetal and adult fast skeletal muscle whereas the Mlc3f promoter is upregulated during fetal development and remains on in adult fast
skeletal muscle. Two enhancer elements have been identified at the mammalian Mlc1f/3f locus, a 3′ element active at all developmental stages and
an intronic enhancer activated during fetal development. Here, using transgenesis, we demonstrate that these enhancers act combinatorially to
confer the spatial, temporal and quantitative expression profile of the endogenous Mlc3f promoter. Using double reporter transgenes we
demonstrate that each enhancer can activate both Mlc1f and Mlc3f promoters in vivo, revealing enhancer sharing rather than exclusive enhancer–
promoter interactions. Finally, we demonstrate that the fetal activated enhancer contains critical E-box myogenic regulatory factor binding sites
and that enhancer activation is impaired in vivo in the absence of myogenin but not in the absence of innervation. Together our observations
provide insights into the regulation of fetal myogenesis and the mechanisms by which temporally distinct genetic programs are integrated at a
single locus.
© 2007 Elsevier Inc. All rights reserved.Keywords: Skeletal muscle development; Enhancer; Transgene; Fetal myogenesis; Gene regulationIntroduction
Skeletal muscle development in utero is biphasic: embryonic
myogenesis takes place between embryonic day (E) 9.5 and
E13.5 in the mouse to generate primary muscle fibers and is
followed during fetal development by secondary myogenesis
which gives rise to the bulk of skeletal muscle fibers present at
birth (Kelly and Zacks, 1969). These successive waves of
myogenesis are undertaken by embryonic and fetal myoblasts
respectively, which have distinct growth factor responses and⁎ Corresponding author. Developmental Biology Institute of Marseille-
Luminy, Inserm Avenir group, CNRS UMR6216, Université de la Méditerranée,
Campus de Luminy Case 907, 13288 Marseilles Cedex 9, France. Fax: +33
491269726.
E-mail address: kelly@ibdml.univ-mrs.fr (R.G. Kelly).
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doi:10.1016/j.ydbio.2007.10.044proliferative and differentiation capacities (Cossu and Molinaro,
1987; Harris et al., 1989; Condon et al., 1990; Barbieri et al.,
1990; Ferrari et al., 1997, Pin et al., 2002). Fetal myogenesis is
accompanied by selective upregulation or activation of a num-
ber of skeletal muscle genes. Evidence that different transcrip-
tional programs operate in embryonic and fetal myoblasts
supports a model by which they correspond to distinct genetic
as well as temporal myogenic lineages (Kassar-Duchossoy
et al., 2004; Biressi et al., 2007). Fetal myogenesis appears to
depend on a Pax3/Pax7 positive progenitor cell population and
activation of the myogenic regulatory factor (MRF) genesMyf5
and MyoD by either Pax3 or Pax7 (Relaix et al., 2005, Kassar-
Duchossoy et al., 2005). MyoD and Myf5, together with the
remaining MRFs myogenin and Mrf4, are essential for the entry
of a cell into the myogenic program and its consequent
differentiation (Tapscott, 2005; Buckingham, 2006). While
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differs from that in the embryo are not well understood, recent
evidence based on global and gene-specific analysis suggests
that late myogenic gene expression is controlled by a MyoD-
driven feed-forward mechanism involving myogenin, the
MADS-box containing transcription factor Mef2D and the
chromatin remodeling enzyme Brg1 (Penn et al., 2004; Ohkawa
et al., 2006).
Analysis of the transcriptional regulation of the murine
Mlc3f promoter provides a tractable system to examine the
mechanisms controlling the embryonic and fetal myogenic
programs. TheMlc1f/3f (Myl1) locus encodes two alkali myosin
light chains, Mlc1f and Mlc3f, from differentially regulated
promoters (Nabeshima et al., 1984; Robert et al., 1984;
Periasamy et al., 1984). In contrast to the Mlc1f promoter,
which is active in embryonic, fetal and adult skeletal muscle, the
Mlc3f promoter is upregulated during fetal development and
remains active in adult skeletal muscle (Barton et al., 1989; Cox
and Buckingham, 1992; McGrew et al., 1996). Transcriptional
regulation at the Mlc1f/3f locus is controlled by a series of
regulatory modules, including elements in the Mlc1f and Mlc3f
promoters and two differentially activated muscle-specific
enhancers (reviewed in Kelly and Buckingham, 2000). An
enhancer located 3′ to the gene (3′ enhancer) is active in
embryonic, fetal and adult skeletal muscle (Donoghue et al.,
1988; Rosenthal et al., 1989; Rao et al., 1996), while a second
enhancer in the first intron (intronic enhancer) is active only in
fetal and adult skeletal muscle (Kelly et al., 1997). Transgenic
experiments have shown that these regulatory elements control
muscle-specificity, temporal regulation, fiber-type specificity
and patterned expression along the anterior–posterior axis
(Grieshammer et al., 1992; Kelly et al., 1995, 1997; McGrew et
al., 1996; Neville et al., 1996; Rao et al., 1996). However, how
the activity of the 3′ and intronic enhancers is integrated at the
Mlc1f/3f locus to regulate differential promoter activities
remains unknown.
Transgenic analysis has revealed that different enhancers are
generally responsible for expression in different cell types or
sub-domains of a particular cell type or tissue, revealing a
modular basis to the control of gene transcription (Arnone and
Davidson, 1997). Distinct cis-acting modules activate a pro-
moter in particular organs, cell-types or spatial domains in
response to particular combinations of trans-acting regulatory
factors, and together recapitulate the endogenous range of
promoter activity. However, less is known about how different
enhancers that function in the same cell type act together to
regulate promoter activity. We therefore investigated the effect
of both enhancers on the Mlc3f promoter in vivo and observed
that they act combinatorially to confer the spatial, temporal and
quantitative expression profile of the endogenous Mlc3f
promoter on an Mlc3f transgene. Using a double reporter gene
system in transgenic mice we observed that both the embryonic
and fetal activated enhancers can act on early and late up-
regulated promoters, ruling out a simple “one enhancer one
promoter” model and revealing enhancer sharing at this locus.
Finally, we focused on the molecular regulation of the fetal-
activated enhancer and found that E-boxes binding themyogenic regulatory factors MyoD and myogenin are required
for enhancer activity in skeletal muscle cells in culture. In vivo,
myogenin was found to be required for correct regulation of fetal
enhancer activity while innervation was not. Our results provide
insight into how embryonic and fetal myogenic programs are
integrated to temporally regulate gene expression.Materials and methods
Mice
Transgenic lines were generated by pronuclear injection using standard
protocols as reported previously (Kelly et al., 1997). The 3f-nlacZ-2, 3f-nlacZ-
2E, and 3f-nlacZ-9 transgenes have been previously described (Kelly et al.,
1995, 1997). Pma mutant mice (Ashby et al., 1993a) were provided by John
Harris (University of Otago, New Zealand), and Myogenin mutant mice (Hasty
et al., 1993) by Eric Olson (University of Texas, Southwestern Medical Centre).
Transgene copy numbers were calculated by quantification of Southern blot
hybridization experiments with an Mlc3f 5′ UTR probe that detects both the
endogenous and transgenic loci using a Phosphorimager. Mice were maintained
under standard housing conditions and embryos dated using E0.5 day as the date
of the vaginal plug. Mice were genotyped using PCR and Southern blot analysis
as described in Kelly et al. (1997).
Construction of double reporter gene plasmids
Details of plasmid construction are available on request. Briefly, the human
placental alkaline phosphatase reporter gene (AP) carrying a polyA sequence
(kindly provided by James Sharpe, MRC, Edinburgh) was cloned into a HpaI
site in the Mlc1f 5′ UTR on a plasmid containing 1.6 kb upstream of the
Mlc1f transcriptional start site, Mlc1f exon 1 and the Mlc1f/3f first intron up
to a SalI site 4.2 kb upstream of the Mlc3f transcriptional start site. A SacII–
SalI fragment containing this entire plasmid insert was placed upstream of the
same SalI site in Mlc3f-nlacZ-9 and Mlc3f-nlacZ-9E constructs (Kelly et al.,
1997).
Transfections and reporter gene assays
Transfections were performed in C2/C7 myoblasts using calcium phos-
phate precipitation, myotubes harvested after 48 h of differentiation and
β-galactosidase and luciferase assays carried out as described (Kelly et al.,
1997). Briefly, β-galactosidase assays were performed on 0.2–7% of cell extract
(from a 6-cm culture dish) as described in Sambrook and Russell (2001), and
using a chemiluminescent reporter assay (Galactolight, Tropix, Bedford, MA)
following the manufacturer’s instructions. Luminescence was measured on a
Berthold luminometer (Model LB-9501). Adult muscles and embryonic tissue
were homogenized and quantified using Biorad protein quantification and the
Tropix Galactolight kit as reported by Kelly et al. (1997).
Eletrophoretic mobility shift assays
Preparation of nuclear extracts and electrophoretic shift analysis were
carried out as described in Catala et al. (1995). Antibodies used were mouse
monoclonal anti-myogenin (clone F5D, Developmental Studies Hybridoma
Bank), anti-MyoD1 (clone 5.8a, DakoCytomation) and rabbit polyclonal anti-
MyoD (gift from Woody Wright).
β-Galactosidase and alkaline phosphatase histology
Embryos and fetuses were dissected and fixed in 4% paraformaldehyde for
20 min to 1 h, while cultured cells were only fixed for 5 min, before extensive
rinses in PBS. To visualize β-galactosidase activity, tissues were incubated
overnight at 37 °C in X-gal solution (4 mM potassium ferrocyanide, 4 mM
potassium ferricyanide, 2 mM MgCl2, 400 μg/ml X-gal and 0.02% NP40 in
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et al. (1995) and Sharpe et al. (1998). Briefly, tissues were first rinsed and then
incubated in 2 mM MgCl2/PBS for 1 h at 65 °C to inactivate endogenous
phosphatases and equilibrated in AP buffer (100 mM Tris–HCl pH 9.5,
100 mM NaCl, 50 mMMgCl2, 0.1% Tween 20 and 2 mM levamisol) for 45 min
before being transferred to BM purple (Roche) or 100 mg/ml BCIP 1 mg/ml
NBT and incubated at room temperature in the dark. Double stained embryos
and cells were incubated in X-gal solution prior to heat inactivation and AP
revelation.
Northern blot analysis
Northern blot analysis was carried out according to standard procedures
(Sambrook and Russell, 2001) using a probe from the 5′ UTR of the Mlc3f
transcript.
In situ hybridization
In situ hybridization using 35S labeled probes was carried out as described
by Kelly et al. (1995); whole-mount in situ hybridization using digoxygenin
labeled probes was carried out according to Kelly et al. (1998). Mlc1f exon1
and intronic probes and Mlc3f splice-specific probes are as described in Kelly
et al. (1998).
Results
The 3′ and intronic enhancers act combinatorially during
development
We previously identified a muscle-specific enhancer in the
first intron of the Mlc1f/3f (Myl1) gene which is activated
during fetal myogenesis and remains active in adult fast
skeletal muscle fibers (Kelly et al., 1997). Intronic enhancer
activity is first detected at E13.5 in particular muscles
including the trapezius, and then increases rapidly, extending
to the majority of skeletal muscles by E18.5 (Kelly et al.,
1997). Fetal activation of transgenes carrying this enhancer,
either in its genomic context (3F-nlacZ-9) or placed upstream
of a Mlc3f promoter (3F-nlacZ-2I), contrasts with the earlyTable 1
Mlc3f-nlacZ transgenic lines
Intronic enhancer 3′ Enhancer Transgenic line Tran
3f-nlacZ-2 a − − 5 8
8 18
10 50
3f-nlacZ-9 a + − 1 2
2 4
3f-nlacZ-2E a − + 1 7
2 7
3f-nlacZ-9E + + 8 2
13 1
1f-AP-3f-nlacZ-11.5 + − 11a 30
11b 20
13 3
1f-AP-3f-nlacZ-11.5E + + 1 3
2 13
4 6
a Described in Kelly et al. (1997).
b Transgene activated in the late fetal period.
c β-Galactosidase but no alkaline phosphatase activity observed at E13.5 and aduexpression of the 3F-nlacZ-2E transgene carrying the Mlc1f/
3f 3′ enhancer element which is first expressed at E9 in the
myotome, the time of activation of the Mlc1f promoter and
4 days before high-level transcription from the Mlc3f
promoter (Kelly et al., 1995; McGrew et al., 1996). The
intronic and 3′ enhancers therefore function as distinct
modules activated in response to temporal transcriptional
programs operative during fetal and embryonic myogenesis
respectively.
In order to investigate how the activity of these two
regulatory modules is integrated in vivo we examined the
effects of the presence of both enhancers in a single transgene
on transcription from the Mlc3f promoter. The 3′ enhancer was
introduced into the 3f-nlacZ-9 construct and two transgenic
lines containing both enhancers were generated (3f-nlacZ-9E;
Table 1). Analysis of the spatiotemporal pattern of reporter gene
activation in these lines revealed that reporter gene expression
initiated in skeletal muscle from E9.5, as in the case of the
3f-nlacZ-2E transgene (Fig. 1A). This result suggested that
the endogenous Mlc3f promoter may also respond to the
embryonic myogenic program. Re-evaluation of endogenous
Mlc3f transcript distribution by whole-mount in situ hybridiza-
tion revealed low level accumulation of Mlc3f transcripts in the
myotome and embryonic muscle masses at E10.5 (Fig. 1B). The
Mlc3f promoter is contained within the primary Mlc1f
transcription unit raising the possibility of hybridization to
unspliced Mlc1f transcripts. However, Mlc3f transcripts were
detected using a riboprobe specific to spliced Mlc3f transcripts
(Fig. 1B) and differed in distribution from Mlc1f transcripts
(Fig. 1D) and, importantly, also from primary Mlc1f transcripts
detected using a riboprobe from the first Mlc1f/3f intron, which
gave a punctate nuclear signal (Fig. 1E). At E12.5 3f-nlacZ-9E
transgene expression was observed throughout the embryonic
skeletal musculature (Figs. 1C, F). Together these results reveal
that activity of the 3′ enhancer is not repressed in the presence
of the intronic enhancer, supporting an activation model forsgene copies Embryonic expression Fetal expression Adult expression
− − −
− − −
− − −
− + +
− + +
+ + +
+ + +
+ + +
+ + +
− + +
− + b +
− + c + c
+ + +
+ + +
+ + +
lt timepoints.
Fig. 1. 3f-nlacZ-9E transgene and endogenous Mlc1f/3f expression in embryonic skeletal muscle. (A) β-Galactosidase activity in an E10.5 3f-nlacZ-9E transgenic
embryo revealing reporter gene expression in the myotome (m) and heart (h) in addition to ectopic expression in the roof plate of the neural tube (arrowhead). (B)
Whole-mount in situ hybridization of a non-transgenic embryo with a Mlc3f-specific riboprobe revealing low level Mlc3f transcription in the myotome (m) at E10.5;
note also expression in the heart (h). (C) X-gal stained cryostat section through an E12.5 3f-nlacZ-9E embryo showing transgene expression in embryonic skeletal
muscle (m) and the roof plate of the neural tube (nt). (D) In situ hybridization of a non-transgenic E10.5 embryo with an Mlc1f-specific riboprobe revealing robust
expression in the myotome (m) but not in the heart. (E) An intronic probe specific for unsplicedMlc1f transcripts is also positive in the myotome (m—note the narrow
myotomal expression domain due to the nuclear signal). (F) β-Galactosidase activity in an E13.5 3f-nlacZ-9E embryo showing transgene expression throughout the
embryonic musculature.
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sponding to a low level of endogenous Mlc3f transcription
during embryonic myogenesis.
Integration of transcriptional programs during fetal
myogenesis
The crural muscles of the hindlimb have been well studied as
a site of the embryonic to fetal transition during skeletal muscle
development (Ontell and Kozeka, 1984; Condon et al., 1990).
The Tibialis Anterior (TA) and Extensor Digitorum Longus
(EDL) are innervated before other crural muscles and express
fetal activated muscle genes including Mlc3f and muscle
creatine kinase (Ckm) prior to other crural muscles (Lyons
et al., 1991; Ontell et al., 1993). The 3f-nlacZ-9 transgene
switches on in the hindlimb at E16.5 (Fig. 2A): this transgene is
first activated in the TA and EDL, whereas other crural muscles,
including the gastrocnemius and soleus, remain β-galactosidase
negative at this stage, and activate the transgene during late fetal
and early post-natal development. In contrast, 3F-nlacZ-2E
transgene expression is equivalent in all hindlimb crural
muscles at E16.5 (Fig. 2C) before being down-regulated after
birth in the soleus muscle as the mature fiber-type distribu-
tion emerges (Kelly et al., 1995). Analysis of expression of the
3f-nlacZ-9E transgene at E16.5 revealed a composite expression
profile: expression was observed in all crural muscles with an
elevated level of expression in the TA and EDL, suggesting thatthe reporter gene responds to both enhancer elements (Fig. 2E).
This composite expression pattern resembles the endogenous
Mlc3f expression profile, since Mlc3f transcripts are detectable
by in situ hybridization at a low level throughout the crural
muscles at E16.5, but are at a markedly higher level in the TA
and EDL (Fig. 2B; Ontell et al., 1993). Mlc1f transcripts, in
contrast, are found at an equivalent level in all crural muscles at
this stage (Fig. 2D). This result demonstrates that the intronic
and 3′ enhancers act in a combinatorial manner on the Mlc3f
promoter.
The time of activation of the intronic enhancer coincides
with innervation of the skeletal musculature during fetal
development. For example, the TA and EDL receive in-
nervation before the other developing crural muscles. In order
to investigate whether motor innervation was required for
intronic enhancer activation, we crossed the 3f-nlacZ-2I
transgene with mice carrying the Peroneal muscular atrophy
(Pma) mutation. Pma mutant mice carry a recessive spon-
taneous mutation specifically affecting the peroneal branch of
the sciatic nerve and so lack motor innervation of certain
hindlimb muscles, in particular the TA and EDL (Ashby et al.,
1993a). Analysis of homozygous Pma mutant embryos at
E16.5 carrying the 3f-nlacZ-2I transgene revealed that, despite
the lack of motor innervation, activation of the transgene
occurred normally in the TA and EDL (Fig. 2F) showing
that motor innervation is not required for intronic enhancer
activation in vivo.
Fig. 2. Mlc3f transgene and endogenous Mlc1f/3f expression in crural hindlimb
muscles. (A) Cryostat section through the lower hindlimb of an E16.5 3f-nlacZ-
9 transgenic embryo stained with X-gal and eosin. Transgene expression at this
stage is detected in the Tibialis Anterior (ta) and Extensor Digitorum Longus
(edl) muscles but not the gastrocnemius (g) or soleus (s) muscles: location of the
fibula (f) and tibia (t) are indicated. Transgene expression is also observed in
limb muscles above the knee (arrowhead). (B) In situ hybridization with an
Mlc3f-specific riboprobe to non-transgenic muscles reveals that endogenous
Mlc3f transcripts are present at a low level throughout the crus and at an
elevated level in the ta and edl. High level Mlc3f expression is also observed in
limb muscles above the knee (arrowheads). (C) Transgene expression is
equivalent in different crural muscles of 3f-nlacZ-2E mice, as is the distribution
of endogenous Mlc1f transcripts (D) in non-transgenic muscles (note that this
probe detects unspliced transcripts resulting in a punctate nuclear signal). (E)
The 3f-nlacZ-9E transgene is expressed throughout the crus, but at a higher level
in the ta and edl, as seen for endogenous Mlc3f transcript distribution (B). (F)
Section through the crural muscles of an E16.5 Pmamutant embryo carrying the
3f-nlacZ-2I transgene showing normal transgene activation in the ta and edl.
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maximal transcription from the Mlc3f promoter in vivo
The observation that endogenous Mlc3f transcripts are up-
regulated during the fetal period, and that in 3f-nlacZ-9E
transgenic mice, the two enhancers act combinatorially such
that the fetal pattern is superimposed upon the embryonic
pattern controlled by the 3′ enhancer, raised the question of
whether the two enhancers interact to regulate the level of
expression from the Mlc3f promoter. To investigate this we
quantified β-galactosidase activity in adult skeletal muscle (Fig.
3A–D). 3f-nlacZ-9E mice retained fast fiber-type specificity of
transgene expression in adult muscle (Fig. 3A). Transgene
activity in skeletal muscle of 3f-nlacZ-9E mice was extremely
high, equivalent to 1.5–2×10−3 enzyme units (2–3 ng of
β-galactosidase protein at 714 U/mg) per μg total extract (0.2–0.3% total protein). Expressed per transgene copy, β-galacto-
sidase activity is at least 10-fold higher than in either 3f-nlacZ-
2E or 3f-nlacZ-9 mice, an effect not observed in extracts from
cardiac muscle where the transgenes are also expressed
(Figs. 3B, C). Indeed, levels of transgene mRNA in skeletal
muscle in both 3f-nlacZ-9E lines are equivalent to endogenous
Mlc3f transcript levels, as detected by northern blot analysis
using a Mlc3f 5′ UTR probe which hybridizes equivalently to
the endogenous and transgenic transcripts (Fig. 3D). The
intronic and 3′ enhancer elements therefore act synergistically
in adult mice to drive maximal transcription from the Mlc3f
promoter specifically in skeletal muscle.
In addition to quantifying transgene activity in adult skeletal
muscle we quantified β-galactosidase activity in extracts from
E12.5 embryos (Fig. 3E–F). At this developmental timepoint
3f-nlacZ-9E transgene activity in limb muscle masses,
expressed as β-galactosidase activity per transgene copy, was
approximately 1.5 times that of 3f-nlacZ-2E mice, while the
transgene is not activated at this stage in skeletal muscle of
3f-nlacZ-9mice (Fig. 3E). At E12.5, therefore, the two enhancers
do not act synergistically in skeletal muscle; the level of
transgene expression per transgene copy is approximately
equivalent in 3f-nlacZ-2E and 3f-nlacZ-9E embryos (Fig. 3F).
β-Galactosidase values per transgene copy in adult EDL are
compared with embryonic hindlimb in Fig. 3G. The increase in
3f-nlacZ-2E transgene expression between these timepoints is
likely to reflect both up-regulation of transgene activity and the
fact that only a sub-population of E12.5 hindlimb cells are
differentiated skeletal muscle compared with the majority of
cells in the adult EDL. There is, however, a 10-fold greater adult/
embryonic differential, which is independent of transgene copy
number, in 3f-nlacZ-9E mice (approximate EDL/E12.5 HL
ratio=100) compared with 3f-nlacZ-2E mice (approximate
EDL/E12.5 HL ratio=10), consistent with a 10-fold greater
up-regulation of promoter activity between these timepoints.
Double reporter constructs reveal enhancer sharing rather
than exclusive enhancer promoter interactions
The above results demonstrate that the 3′ and intronic
enhancers at the Mlc1f/3f locus are activated during embryonic
and fetal myogenesis respectively and act together to control
spatiotemporal transcription from the Mlc3f promoter. How-
ever, given that there is high level transcription from the Mlc1f
promoter in embryonic skeletal muscle it is possible that at the
endogenous Mlc1f/3f locus enhancer–promoter interactions are
largely exclusive, such that the 3′ enhancer interacts with the
Mlc1f promoter and the intronic enhancer with the Mlc3f
promoter. In order to investigate whether addition of the Mlc1f
promoter modifies enhancer activity at the Mlc3f promoter and
whether the intronic enhancer can interact with the Mlc1f
promoter in vivo, we generated a DNA construct containing
both promoters, both enhancers and two reporter genes: the
nlacZ reporter gene under transcriptional control of the Mlc3f
promoter and the human placental alkaline phosphatase (AP)
reporter gene under transcriptional control of the Mlc1f pro-
moter (containing 1.6 kb upstream of the Mlc1f transcriptional
Fig. 3. Quantitative analysis of reporter gene expression in Mlc3f transgenic lines. (A) Mean β-galactosidase levels plus S.E.M. (expressed on a logarithmic scale as relative light units per μg protein) are shown for
various adult tissues of the two transgenic lines (13 and 8) carrying construct 3f-nlacZ-9E; EDL, extensor digitorum longus; SOL, soleus; MASS, masseter; KID, kidney; LV, left ventricle. Four adult (2–6 months)
heterozygous mice were assayed per line; EDL and SOL values were determined in duplicate for each animal and represent the mean and S.E.M. of eight muscles. Background β-galactosidase activities in non-transgenic
adult mice are indicated by broken lines and represent high and low extremes (KID and EDL respectively). (B, C) Comparison of mean β-galactosidase levels expressed per transgene copy number for various Mlc3f-
nlacZ transgenic lines in skeletal muscle (EDL) and cardiac muscle (Heart). (D) Northern blot analysis of transgene (arrowhead) and endogenous (arrow) Mlc3f mRNA accumulation in EDL muscles dissected from
variousMlc3f-nlacZ transgenic lines containing either, both or noMlc1f/3f enhancers: 1, 3f-nlacZ-9 line 1; 2, 3f-nlacZ-9 line 2; 3, 3f-nlacZ-2E line 2; 4, 3f-nlacZ-2E, line 1; 5, 3f-nlacZ-9E line 8; 6, 3f-nlacZ-9E line 13;
7, 3f-nlacZ-2 line 5; 8, 3f-nlacZ-2 line 8; 9, 3f-nlacZ-2 line 10; 10, non-transgenic control. The 5′ UTR probe hybridizes equivalently to transgenic and endogenous transcripts. (E) Mean β-galactosidase levels plus S.E.
M. in protein extracts from E12.5 forelimb (FL), hindlimb (HL) and heart (H) for variousMlc3f-nlacZ transgenic lines (mean values for at least five embryos). Background β-galactosidase activities obtained from non-
transgenic embryos are indicated by broken lines and represent high and low extremes. (F) Expression levels per transgene copy, showing that the level of skeletal muscle activity per copy at E12.5 is approximately
equivalent in 3f-nalcZ-2E and 3f-nlacZ-9E embryos. (G) Comparison of transgene activities in E12.5 hindlimbs (HL) and adult EDL extracts.
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426 P.S. Zammit et al. / Developmental Biology 313 (2008) 420–433start site; construct 1f-AP-3f-nlacZ-11.5E; Fig. 4A). The activity
of both reporter genes can therefore be analyzed by whole-
mount or histological analysis in the same embryo (Cepko et al.,
1995; Sharpe et al., 1998). A second construct contained both
promoters and both reporter genes but only the intronic
enhancer (1f-AP-3f-nlacZ-11.5; Fig. 4A). Transient transfection
of these reporter constructs into C2/C7 myotubes revealed
efficient activity of both nlacZ and AP reporter genes which
could be detected simultaneously: β-galactosidase underFig. 4. Analysis of enhancer–promoter interactions at the Mlc1f/3f locus using dou
relative position of the intronic (yellow) and 3′ (green) enhancer elements and the str
C7 myotubes transfected with construct 1f-AP-3f-nlacZ-11.5E and stained for alka
(intense blue) under control of theMlc3f promoter and membrane bound alkaline pho
transgene expression in the myotomal compartment of the somites (brackets) of an E
reporter genes are expressed: note the centrally aligned nuclei positive for β-galactosi
3f-nlacZ-11.5E transgene expression in an E10.5 embryo stained for alkaline phos
myotome (m) but only β-galactosidase activity is observed in the heart (h). (E) At E1
Cryostat section from a 1f-AP-3f-nlacZ-11.5E E16.5 hindlimb stained for alkaline pho
a similar distribution of reporter gene activity is observed for β-galactosidase (G). (H
separately for alkaline phosphatase (top) and β-galactosidase (bottom). Note that bot
(EDL) than the soleus (Sol), reflecting fast fiber specificity. (I) 1f-AP-3f-nlacZ-11.5 tr
galactosidase activity. This transgene lacks the 3′ enhancer and neither reporter gene
heart (h). (J) At E14.5 activation of both reporter genes in 1f-AP-3f-nlacZ-11.5 line 11
that observed for the 3f-nlacZ-9 transgene (Kelly et al., 1997).control of the Mlc3f promoter is localized to the nuclear
membrane whereas AP, under control of the Mlc1f promoter, is
localized on the cytoplasmic surface of the cell membrane
(Fig. 4B).
Transgenic lines were generated carrying these reporter
constructs and the spatiotemporal pattern of reporter gene
activity scored (Fig. 4 and Table 1). In the case of the 1f-AP-3f-
nlacZ-11.5E transgene containing both promoters, reporter
genes and enhancers (three lines) nlacZ activity was observedble reporter transgenes. (A) Cartoon of the murine Mlc1f/3f locus showing the
ucture of the 1f-AP-3f-nlacZ-11.5E and 1f-AP-3f-nlacZ-11.5 transgenes. (B) C2/
line phosphatase and β-galactosidase activity showing nuclear β-galactosidase
sphatase (purple) under control of theMlc1f promoter. (C) 1f-AP-3f-nlacZ-11.5E
10.5 embryo stained for alkaline phosphatase and β-galactosidase activity. Both
dase in contrast to the myotome spanning alkaline phosphatase signal. (D) 1f-AP-
phatase and β-galactosidase activity. Both reporter genes are expressed in the
3.5 both reporter genes are expressed throughout the embryonic musculature. (F)
sphatase activity: note the elevated expression in the TA and EDL (arrowheads);
) 1f-AP-3f-nlacZ-11.5E transgene expression in adult hindlimb muscles stained
h reporter genes are expressed at a higher level in the extensor digitorum longus
ansgene expression in an E10.5 embryo stained for alkaline phosphatase and β-
is expressed in the myotome; however β-galactosidase activity is observed in the
a embryos has initiated in axial and proximal limb muscles, in a similar profile to
427P.S. Zammit et al. / Developmental Biology 313 (2008) 420–433from E9.5, as in the case of the 3f-nlacZ-9E transgene, revealing
that the presence of the Mlc1f promoter did not deplete activity
of the 3′ enhancer from the Mlc3f promoter in embryonic
skeletal muscle (Figs. 4C, D). nlacZ activity was also observed
in fetal and adult fast skeletal muscles fibers with this transgene
(Figs. 4E, H). Similarly, AP activity was present from E9.5 and
at all subsequent stages (Figs. 4C–H). Analysis of crural
muscles at E16.5 revealed that the 3′ and intronic enhancers
act combinatorially on both the Mlc1f and Mlc3f promoters:
β-galactosidase and alkaline phosphatase activity were elevated
in the TA and EDL relative to the gastrocnemius (Figs. 4F, G).
Both reporter genes displayed a fast fiber-specific expression
profile in adult skeletal muscle (Fig. 4H). Minor differences in
the temporal activation of AP and nlacZ reporter genes were
observed in second arch-derived craniofacial muscles, which
activated AP under control of the Mlc1f promoter before nlacZ
(Fig. 4E). In the case of the 1f-AP-3f-nlacZ-11.5 transgene
containing both promoters, reporter genes and the intronic
enhancer, but lacking the 3′ enhancer (three lines), neither
promoter was active in embryonic skeletal muscle prior to
E12.5 in any line (Fig. 4I). In two lines, both AP and nlacZ
reporter genes were activated during the fetal period, consistent
with the ability of the Mlc1f promoter to respond to the activity
of the intronic enhancer suggested by the fetal upregulation
observed in the 1f-AP-3f-nlacZ-11.5E lines (Fig. 4J). Timing of
onset varied between these lines though, with one active from
E13.5 while the other was delayed to late fetal stages. In the
third line the nlacZ but not AP reporter gene was activated from
E13.5 (Table 1). Each enhancer can therefore interact with each
promoter revealing the prevalence of enhancer sharing rather
than exclusive enhancer–promoter interactions at the Mlc1f/3f
locus.
E-boxes regulate activity of the intronic enhancer
We subsequently investigated the molecular mechanisms
responsible for activation of the intronic enhancer using
myogenic cells in culture and mutant mouse lines. Our previous
work delimited the intronic enhancer to an 800 bp element
between 4.2 and 5 kb upstream of the Mlc3f promoter (Kelly
et al., 1997). This enhancer contains six E-box consensus
binding sites (termed A–F), targets for MRF basic–helix–loop–
helix transcriptional activators (Fig. 5A). Also present is an A/T-
rich sequence containing a single mismatch with a Mef2 site in
the 5′ enhancer of the Ckm gene (Gossett et al., 1989), located
between E-boxes C and D (Fig. 5A). Since E-boxes and Mef2
sites are critically required for the regulation of many muscle-
specific genes, including late-activated genes, we explored the
requirement for these sites in enhancer function using deletion
and mutational analysis assayed by transient transfection in
C2/C7 myotubes.
Deletions removing regions containing E-boxes A and B
from a construct containing 5 kb upstream of the Mlc3f
transcription initiation site (3f-nlacZ-5) had only a marginal
effect on transcriptional activity of the Mlc3f promoter. A
bigger deletion however, also including a region containing
E-boxes C and D and the A/T rich sequence, drastically reducedactivity to that of the control 2 kb Mlc3f promoter alone (data
not shown). Since the transcriptional activity of 3f-nlacZ-5 is
indistinguishable from that of a construct containing the 800 bp
intronic enhancer upstream of a 2 kb promoter, 3f-nlacZ-2I, we
used this to test the effects of single and combined mutations of
E-boxes A–F and the A/T rich sequence (Fig. 5B). Only
mutations of E-boxes C and F resulted in significantly reduced
reporter gene activity. Mutation of either E-box C or F re-
duced activity of the Mlc3f promoter to approximately 60% of
3f-nlacZ-2I control levels, while simultaneous mutations in both
E-boxes C and F had an additive effect, resulting in activity of
only ∼45% of control levels (Fig. 5B). Mutation of the Mef2c
site alone did not significantly reduce activity compared to
control, and when the Mef2c site was mutated together with all
E-boxes in the intronic enhancer, activity was not significantly
different to when just both E-box C and F were mutated
(Fig. 5B). These results demonstrate that intronic enhancer
activity is primarily regulated by E-boxes.
MyoD and myogenin bind to the intronic enhancer
Having established that E-box mutations in the intronic
enhancer significantly affected transcriptional activity of the
Mlc3f promoter, we next investigated the DNA binding proper-
ties of E-boxes C, E and F using gel retardation analysis.
Radioactively labeled oligonucleotides containing E-boxes C, E
and F formed complexes after incubation with nuclear extract
prepared from differentiated C2 myotubes; both E-boxes C and
E bound the same large molecular weight complex, as shown by
successful competition of E-box C with unlabelled E-box E and
vice versa (Fig. 5C). E-box F however, failed to bind this
complex. In addition, E-box C also bound lower molecular
weight complexes, absent from E-box E, which were not
competed by unlabelled E-box E (Fig. 5C, lane 5). Interestingly,
E-box F also bound the same lower molecular weight complexes
as E-box C, as shown by successful competition with unlabelled
E-box C (Fig. 5C, lane 16) and vice versa (Fig. 5C, lane 9).
To characterize the proteins in these complexes, we used
antibodies specific to MyoD, which caused a super-shift of a
lower molecular weight complex formed with E-boxes C
(Fig. 5C, lane 3) and F, but not of complexes formed by E-box E
(Fig. 5C, lane 14). Similarly, incubation with antibodies specific
to myogenin also caused a super-shift of lower molecular
weight complexes in E-boxes C (Fig. 5C, lane 2) and F (Fig. 5C,
lane 19), but not with E-box E (Fig. 5C, lane 13). Competition
of E-box C with unlabelled E-box F and vice versa, but not
E-box E, prevented a shift in the presence of MyoD (Fig. 5C,
compare lanes 7 and 11) and myogenin antibodies (Fig. 5C,
compare lanes 6 and 10), confirming that MyoD and myogenin
bind to both E-box C and F. To confirm that the E-boxes, and
not the flanking sequences, were responsible for binding
complexes, oligonucleotides were prepared incorporating
mutations to E-box C, E and F (Fig. 5A). These oligonucleo-
tides failed to form complexes and were unable to compete the
complexes formed by the wild type E-boxes (data not shown).
MyoD and myogenin can therefore interact directly with the
intronic enhancer element, binding to the two E-boxes which
Fig. 5. Molecular analysis of theMlc1f/3f intronic enhancer. (A) DNA sequence of the murine intronic enhancer showing the position of E-boxes C–F and the Mef2-
related site (M). Introduced mutations are indicated under each site. (B) Mutation analysis of candidate transcription factor binding sites in the 800 bp intronic enhancer
assayed in C2/C7 myotubes. The mutations introduced in E-boxes C and F (see panel A) significantly reduced enhancer activity, having an accumulative effect when
both were mutated in 3f-nlacZ-2I. Mutation of the Mef2-related site in conjugation with mutations in E-boxes A–F did not further reduce activity. Reporter gene
expression is presented relative to 3f-nlacZ-2I (100%) and represents the mean of at least six data points from three experiments. (C) Electrophoretic mobility shift
assays using radiolabelled oligonucleotide probes containing the indicated E-box motifs after incubation with C2/C7 myotube nuclear extract. The complexes bound
by E-box C (lane 1) and F (lane 15), but not E-box E (lane 12), contain myogenin and MyoD, as shown by a super-shift after pre-incubation of the nuclear extract with
antibodies specific to myogenin (Mg—arrow, compare lanes 2, 6 and 19 with 13) and MyoD (MD—arrowhead, compare lanes 3 and 7 with 14). The presence of
unlabelled competitor oligonucleotides of E-box F (lanes 10 and 11) prevented this shift with E-Box C, confirming that E-box F also binds MyoD and myogenin,
whereas unlabelled E-box E (lanes 6 and 7) was unable to compete.
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myotubes.
Myogenin controls the timing of intronic enhancer activation in
vivo
The above in vitro analysis revealed that the activity of the
intronic enhancer is controlled by E-boxes, two of which bindmyogenin and MyoD. Of the different MRF mutations which
have been analyzed, Myogenin mutant embryos have a
phenotype specifically affecting fetal myogenesis: mutant
mice have relatively normal primary myogenesis but perturbed
secondary myogenesis, resulting in a failure of fetal myoblasts
to differentiate and severe muscle hypoplasia at birth (Hasty et
al., 1993; Nabeshima et al., 1993; Venuti et al., 1995). This
phenotype is consistent with a feed-forward model of late
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previously bound by MyoD, together with Mef2D and the
chromatin remodeling enzyme Brg1 (Penn et al., 2004; Ohkawa
et al., 2007). Given that myogenin binds to functional E-box
motifs in the fetal-activated Mlc1f/3f intronic enhancer we
investigated whether myogenin contributes to the control of
intronic enhancer activation in vivo. Transgenic mice contain-
ing the intronic (3f-nlacZ-9) or 3′ (3f-nlacZ-2E) Mlc1f/3f
enhancers were crossed to mice heterozygous for a Myogenin
null allele (Hasty et al., 1993). After crossing heterozygous
mutant mice carrying either transgene, reporter gene expression
was scored in myogenin null embryos and control littermates.
This analysis revealed that the 3f-nlacZ-2E transgene, contain-
ing the 3′ enhancer element, was normally activated during
embryogenesis and remained expressed in the absence of
myogenin at E13.5 (Figs. 6A and D). However, no activation of
the intronic enhancer regulated transgene was observed at this
stage (compare wt in Fig. 6B, with Myog−/− in 6E). Activation
of the 3f-nlacZ-9 transgene was delayed by 3–4 days in the
absence of myogenin and only low level transgene expression
was observed in a small number of skeletal muscle fibers at
E17.5 (compare wt in Fig. 6C with Myog−/− in 6F), in a similar
distribution to the reported appearance of perinatal–myosin
heavy chain expression and likely reflecting the severe
deficiency in muscle at this stage (Venuti et al., 1995). TheFig. 6. Analysis of Mlc3f transgene expression in Myogenin−/− embryos. (A) X-gal s
the embryonic musculature. (B) The Mlc3f-nlacZ-9 transgene is activated at this sta
forming trapezius muscles (arrows). (C) Bisected E17.5Mlc3f-nlacZ-9 embryo show
heart (h). (D) An approximately normal expression profile of the 3f-nlacZ-2E transge
embryos (arrowhead). (E) In contrast, the 3f-nlacZ-9 transgene fails to be activated a
transgene positive fibers are observed in Myogenin−/− embryos whereas normal trandefined requirement for myogenin during fetal myogenesis thus
contributes to control the time of activation of theMlc3f intronic
enhancer during normal development.
Discussion
The biphasic transcriptional regulation of the Mlc1f/3f locus
provides a model of how gene expression is controlled during
embryonic versus fetal myogenesis. Our results suggest that the
3′ and intronic enhancers act combinatorially to regulate
spatiotemporal Mlc3f transcription and synergistically to confer
maximal transcription rates in adult skeletal muscle. Together
the spatiotemporal pattern and level of transgene expression in
the presence of both enhancers approach that of the endogenous
Mlc3f gene, indicating that the 3f-nlacZ-9E construct may
contain all the regulatory elements necessary for normal
activation of this promoter. In the presence of both enhancers,
β-galactosidase activity per transgene copy is an order of
magnitude higher than in 3f-nlacZ-2E or 3f-nlacZ-9 mice. This
synergistic effect is specific to adult skeletal muscle and is not
observed in cardiac muscle, another site of transgene expres-
sion. This combination of regulatory elements thus defines a
regulatory cassette capable of driving extremely high levels of
skeletal muscle expression of potential interest for gene therapy
applications.tained E13.5 Mlc3f-nlacZ-2E embryo showing transgene expression throughout
ge in specific dorsal muscles including the cervical and thoracic regions of the
ing that at this stage, the transgene is widely expressed in skeletal muscle and the
ne is observed in Myogenin−/− embryos; note the edema characteristic of mutant
t E13.5 in the absence of myogenin. (F) At E17.5 a small number of 3f-nlacZ-9
sgene expression is observed in the heart.
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synergistic effect in the presence of both enhancers is observed
in embryonic skeletal muscle. The differential between
embryonic and adult hindlimb β-galactosidase activity is
therefore 10-fold greater when both enhancers are present
than when only the 3′ enhancer is present in the transgene, a
fold difference which is independent of transgene copy number.
These data are consistent with the marked up-regulation of
Mlc3f as opposed to Mlc1f transcription in fetal skeletal muscle
(Cox and Buckingham, 1992; McGrew et al., 1996). Cox and
Buckingham (1992) estimated by nuclear run-on analysis, using
nuclei isolated from hindlimb skeletal muscle, that whereas
Mlc1f transcription increases 2-fold between E14.5 and E18.5,
Mlc3f transcription increases 14-fold in the same period to
attain the level of activity of Mlc1f. Our data suggest that this
substantial increase in Mlc3f transcription rate results from late
activation of the intronic enhancer at E13.5, coupled with
promoter-selective synergy (see below).
Other muscle-specific genes have been shown to contain
more than one enhancer, each of which may regulate distinct
subsets of transcriptional specificities (Johnson et al., 1989;
Gremke et al., 1993; Zhu et al., 1995). A similar phenomenon of
in vivo synergy in adult skeletal muscle has also been
demonstrated in MCK-CAT transgenic mice, where a 5′
enhancer interacts with a sequence immediately upstream of
the promoter to drive transcriptional activity in skeletal and
cardiac muscle at a higher level than that observed with either
cis-acting element alone (Donoviel et al., 1996). Functionally
identical pairs of enhancers at the Drosophila Troponin I, Tro-
ponin T and Paramyosin loci have been shown to interact
synergistically to control correct expression levels; in the case
of Troponin T, synergism was higher in larval than adult
muscles (Marin et al., 2004; Mas et al., 2004; Marco-Ferreres et
al., 2005). Together with our results, these findings support the
view that spatiotemporal specificity and maximal transcription
levels in vivo depend on the concerted activities of distinct cis-
acting regulatory sequences.
The 3f-nlacZ-9 construct lacks regulatory elements present
at the endogenous locus, including the Mlc1f promoter and 3′
enhancer, whereas the presence of both enhancers in 3f-nlacZ-
9E mice may more closely approximate the endogenous
situation. However, the Mlc1f promoter is also present at the
endogenous locus, and since both enhancers can act on both
promoters it was important to investigate the promoter
specificities of the enhancer elements during development and
in adult skeletal muscle. We addressed this question in
transgenic mice containing nlacZ under control of the Mlc3f
promoter and an alkaline phosphatase reporter gene under
control of the Mlc1f promoter. A similar two reporter system
has been used to analyze enhancer–promoter interactions at the
Hoxb locus, revealing evidence for selectivity, sharing and
competitive interactions which may contribute to the main-
tenance of Hox gene organization (Sharpe et al., 1998). Our
results revealed no evidence for selectivity or competition in the
regulation of the Mlc1f and Mlc3f promoters. Instead we
observed that the 3′ enhancer continues to direct transcription
from the Mlc3f promoter in embryonic skeletal muscle in thepresence of theMlc1f promoter, and that in the absence of the 3′
enhancer the intronic enhancer activates the Mlc1f promoter as
well as theMlc3f promoter during the fetal period. Rather than a
“one enhancer one promoter” model of transcriptional control,
enhancer sharing appears to dominate at the Mlc1f/3f locus.
This may be achieved by a dynamic flip-flop mechanism, as
proposed in the case of the β-globin gene cluster (Wijgerde
et al., 1995) or by independent activation of the Mlc1f and
Mlc3f promoters in different nuclei within syncitial myotubes.
Mononuclear embryonic myocytes were observed to express
both reporter genes, thus arguing in favor of a dynamic flip-flop
mechanism. However, given that theMlc3f promoter lies within
the Mlc1f primary transcription domain, in contrast to the
situation at adjacent promoters in the β-globin or Hox loci, a
third possibility is allele-specific transcription of each promoter.
Why theMlc3f rather thanMlc1f promoter should be selectively
upregulated during fetal myogenesis remains to be explained in
the light of an enhancer sharing model. We favor the hypothesis
that the synergistic effect of the intronic and 3′ enhancers on the
level of reporter gene expression may be specific to the Mlc3f
promoter. Quantification of Mlc1f promoter activity in the
presence of each enhancer alone versus both enhancers may
resolve this issue. Interestingly, synergy between enhancer
elements has been reported at the kappa immunoglobulin light
chain locus in B-cell lines (Blasquez et al., 1992; Fulton and
Van Ness, 1993). High level transcription from a kappa V-
region promoter is dependent on two enhancer elements which
are activated at different stages of B-cell maturation, and which
synergize to effect maximal transcription levels (Fulton and Van
Ness, 1993). Like theMlc1f/3f gene, the kappa immunoglobulin
light chain gene uses two promoters only one of which supports
synergistic enhancer activity. Promoter-selective enhancer
synergy therefore provides a mechanism by which enhancer–
promoter interactions may control the developmental modula-
tion of gene expression. Our results point to the importance of
such mechanisms in vivo, and complement models of enhancer
action at other loci containing multiple promoters (Wijgerde
et al., 1995; Sharpe et al., 1998; Spitz et al., 2005).
We have shown that transcriptional activity of the intronic
enhancer in cultured myotubes is E-box driven, with both
MyoD and myogenin binding specifically. The 3′ enhancer also
contains multiple E-box motifs required for activity in muscle
cells in culture and in transgenic mice (Wentworth et al., 1991;
Rao et al., 1996). Our observation that the intronic enhancer
fails to be activated at E13.5 in the absence of myogenin,
whereas the activity of the 3′ enhancer is unaffected, suggests
that a differential response of the enhancers to different MRFs
may contribute to the temporal regulation of transcription at the
Mlc1f/3f locus. The timing of MRF protein accumulation during
development and the analysis of MRF null phenotypes suggests
that myogenin is the principal MRF driving differentiation at the
time of onset of intronic enhancer activation (see Tajbakhsh and
Buckingham, 2000). The avian Mlc1f/3f gene has also been
shown to have two enhancers, in this case both upstream of the
Mlc1f promoter, one of which is MyoD responsive and one
myogenin responsive (Asakura et al., 1993). Of the MRFs,
MyoD was found to be most efficient at transactivating the
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al., 1990). BC3H and L6E9 cells express Mlc3f but not Mlc1f
transcripts and upregulate Mlc1f expression on MyoD transfec-
tion (Brennan et al., 1990; Muthuchamy et al., 1992). The
intronic enhancer may therefore be selectively responsive to
myogenin, which plays a critical role in generating muscle fiber
mass during fetal myogenesis (Venuti et al., 1995). Indeed, a
number of selective in vivo myogenin targets have recently
been identified (Davie et al., 2007). Analysis of conditional
mutant mice lacking myogenin in postnatal muscle suggests that
myogenin does not play a role in transcriptional regulation of
contractile protein encoding genes after birth (Knapp et al.,
2006); once activated, the intronic and 3′ enhancer elements
may be regulated by common mechanisms.
An alternative hypothesis is suggested by the recent finding
that MyoD and myogenin have distinct regulatory roles at a
similar set of target genes (Tapscott, 2005). Global and gene-
specific analyses have shown that a feed-forward mechanism
driven by MyoD underlies the temporal regulation of myogenic
gene expression both in cell culture systems and during
development. MyoD binding is sufficient to activate early
myogenic regulatory genes whereas late activated genes are
regulated by myogenin, Mef2D and the chromatin remodeling
enzyme Brg1 (Penn et al., 2004; Cao et al., 2006; Ohkawa et al.,
2006). During embryonic development MyoD protein accumu-
lates after the onset of myogenesis suggesting a role for Mrf4 in
myotome differentiation (see Tajbakhsh and Buckingham,
2000). Activation of late myogenic genes is dependent on
prior MyoD-mediated regional histone modification and
activation of the p38 mitogen activated protein kinase pathway
(Penn et al., 2004; Ohkawa et al., 2007). Such a MyoD-driven
feed-forward mechanism may operate at the Mlc1f/3f intronic
enhancer; furthermore, our results suggest that sequential
activation of early and late myogenic regulatory elements may
take place at a single locus.
While E-box sites appear to be key regulatory elements
controlling activity of the intronic and 3′ enhancers, additional
transacting factors binding in the context of these two regulatory
elements may also contribute to the different time of activation
of these regulatory elements (Ferrari et al., 1997; Ernst et al.,
1991; Gong et al., 1997; Ceccarelli et al., 1999; Penn et al.,
2004; Ohkawa et al., 2007). Investigation of occupancy of the 3′
and intronic enhancers by chromatin immunoprecipitation with
embryonic and fetal tissue will provide further insights into the
molecular mechanisms controlling temporal gene expression at
this locus.
In contrast to the importance of myogenin in fetal activation
of the intronic enhancer, we demonstrate that activation is
independent of innervation. Nerve–muscle contacts are estab-
lished during the fetal period and innervation has been
implicated in fetal upregulation of Mlc3f transcription. In
avians, innervation was shown to be required for limb bud grafts
to accumulate Mlc3f protein whereas aneural grafts accumu-
lated only Mlc1f protein (Merrifield and Konigsberg, 1987). In
utero injection of β-bungarotoxin in mice causing the
destruction of peripheral nerves resulted in a major decrease
inMlc3f transcript accumulation (Barton et al., 1989); similarly,laser ablation of the lumbrosacral spinal cord at E14 prevented
high level Mlc3f transcript accumulation in the hindlimb
(Washabaugh et al., 1998). Despite this evidence for a role of
neural influences on upregulation of Mlc3f expression we
observed that the intronic enhancer is activated at the correct
time in aneural hindlimb muscles of Pma mutant mice.
Secondary myogenesis is known to occur relatively normally
in aneural Pma hindlimb muscles, although this is perturbed by
chronic paralysis induced by tetrodotoxin (Ashby et al., 1993b).
Spontaneous contraction and passive stretch of aneural muscles
in an otherwise innvervated limb, may therefore be sufficient for
secondary myogenesis and possibly also for Mlc3f upregula-
tion, indicating that direct nerve/muscle contact and electrical
activity may not be necessary.
In conclusion, we have shown that the two regulatory
modules characterized at the Mlc1f/3f locus act combinatorially
to control spatiotemporal gene activation and synergistically to
drive high level transcription; furthermore, the activities of these
enhancers are non-exclusive but are shared by the Mlc1f and
Mlc3f promoters. The fetal activation of one of these enhancers
provides a direct demonstration of how myogenin orchestrates
fetal myogenesis. These results provide insights into how
biphasic myogenic programs impact on gene expression and
how separate regulatory modules act together to control
transcription from target promoters.
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